Morana Jovan-Embiricos

Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.

Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.

Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.

Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.

Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.

Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.

ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.

ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY.

Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.

ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.

Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.